Animal Dosing Vehicle Selection

Controlling the Dosing Vehicle to Generate Reliable Preclinical PK Data

The choice and preparation of the animal dosing vehicle directly determines the quality and interpretability of preclinical PK, efficacy, and toxicology data. Variability in the dosed solid form, particle size, or vehicle stability introduces dose-to-dose inconsistency that can result in non-proportional PK, misleading bioavailability estimates, and failed Tox studies. Crystal Pharmatech applies a systematic, science-driven approach to vehicle selection and preparation that eliminates this guesswork.

Vehicle Types and How We Select Between Them

Vehicle selection is driven by the API's aqueous solubility, dose level, target species, and route of administration.

Vehicle Type	Best Used When
Aqueous Solution	API has sufficient solubility at the required dose concentration across the physiological pH range
Co-solvent / Surfactant System	Aqueous solubility insufficient for a clear solution; ionization or buffering alone cannot achieve target concentration
Cyclodextrin Complexation	Solution required but co-solvents cannot achieve target exposure; compound shows inclusion complex formation with HP-β-CD
Suspension	Required dose concentration exceeds what any solution-based vehicle can achieve
Enabling Formulation Vehicle	No solution or conventional suspension can achieve adequate in vivo exposure; compound is highly lipophilic (high LogD) or requires particle size reduction

What We Analytically Control Before Every Study

Regardless of vehicle type, Crystal Pharmatech verifies the following for every dosing formulation before it is used in an in vivo study:

Solid form of the dosed API

Particle size distribution

API concentration and dose homogeneity

Chemical and physical stability over the in-use period

Gavageability

In vitro biorelevant dissolution (for suspensions)

Achieve Your Success with Our Expertise

Have a question or need support with your project? Please complete the form, and our team will get back to you shortly.  

Our capabilities span three specialized platforms:

Small Molecule
Crystal Bio Solutions
Crystal NAX

By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your inquiry. The information you submit will be governed by our Privacy Policy.